literature

HIV mutation literature information.

Transmitted HIV-1 drug resistance in a large international cohort using next-generation sequencing: results from the Strategic Timing of Antiretroviral Treatment (START) study.

PMID: 33369017 2021 HIV medicine

Method: INSTI mutations, which are not included on this list, were defined as those on the Stanford HIVdb surveillance DRM list, namely T66AIK, E92Q, F121Y, G140ACS, Y143CHR, S147G, Q148HKR and N155HS.

Virologic outcomes of switching to dolutegravir functional mono- or dual therapy with a non-cytosine nucleoside analog: a retrospective study of treatment-experienced, patients living with HIV.

PMID: 33941212 2021 AIDS research and therapy

Method: Patients with the following baseline mutations associated with reduced susceptibility to DTG: T66K, E92Q, G118R, E138 K/A/T, G140 S/A/C, Q148 H/R/K, N155H and R263K were excluded.

Cellular Immune Response Induced by DNA Immunization of Mice with Drug Resistant Integrases of HIV-1 Clade A Offers Partial Protection against Growth and Metastatic Activity of Integrase-Expressing Adenocarcinoma Cells.

PMID: 34199989 2021 Microorganisms

Abstract: We designed DNA-vaccines against drug-resistant HIV-1 based on consensus clade A integrase (

Method: Raltegravir-resistant IN_a variants with two patterns of primary resistance to RAL: L74M, E92Q, V151I, N155H, G163R (IN_a_r1) and E138K, G140S, Q148K (IN_a_r2), and their variants inactivated by mutation D64V (IN_in_r1 and IN_in_r2) were generated by site-directed mutagenesis of pETIN_a using the QuikChange II Site-Directed Mutagenesis kit (Agilent Technologies, Santa Clara, CA, USA) with generation of plasmids pETIN_a_r1, pETIN_a_r2, pETIN_in_r1, and pETIN_in_r2, respectively.

Integrase strand transfer inhibitor (INSTI)-resistance mutations for the surveillance of transmitted HIV-1 drug resistance.

PMID: 31617907 2020 The Journal of antimicrobial chemotherapy

Abstract: Among the 29 relatively common INSTI-selected mutations, 24 emerged as candidates for inclusion on a list of INSTI surveillance drug-resistance mutations: T66A/I/K, E92G/Q, G118R, F121Y, E138A/K/T, G140A/C/S, Y143C/H/R/S, S147G, Q148H/R/K, N155H, S230R and R263K.

Expanded Spectrum of Antiretroviral-Selected Mutations in Human Immunodeficiency Virus Type 2.

PMID: 31965175 2020 The Journal of infectious diseases

Abstract: In IN, 11 nonpolymorphic TSMs occurred in >=4 persons: Q91R, E92AQ, T97A, G140S, Y143G, Q148R, A153G, N155H, H156R, R231 5-amino acid insertions.

HIV-1 acquired drug resistance to integrase inhibitors in a cohort of antiretroviral therapy multi-experienced Mexican patients failing to raltegravir: a cross-sectional study.

PMID: 32041622 2020 AIDS research and therapy

Table: E92Q

Molecular dynamic simulations to investigate the structural impact of known drug resistance mutations on HIV-1C Integrase-Dolutegravir binding.

PMID: 32379830 2020 PloS one

Result: Calculation of the covariance matrix values after diagonalization showed a significant increase for the G140S system (18.33 nm) compared to the other three systems WT, E92Q and Y143R each having 9.58 nm, 8.98 nm and 10.41 nm lower values, respectively.

Result: Distance analysis indicated a smaller average distance of 0.21 +- 0.01 nm and 0.22 +- 0.01 nm between the WT, Y143R MG ion and drug DTG systems compared to E92Q and G140S each having a distance of 0.41 +- 0.04 nm, 0.99 +- 0.20 nm, respectively.

Result: On the other hand, the E92Q system showed interactions with one of the active site residues (D116) but no MG ionic interactions (Table 3).

Virologic suppression in patients with a documented M184V/I mutation based on the number of active agents in the antiretroviral regimen.

PMID: 33014372 2020 SAGE open medicine

Table: E92Q

Variability in HIV-1 Integrase Gene and 3'-Polypurine Tract Sequences in Cameroon Clinical Isolates, and Implications for Integrase Inhibitors Efficacy.

PMID: 32106437 2020 International journal of molecular sciences

Discussion: The aa substitutions E92Q, S119R, E138A, Y143R, G148H/R, and S230R/N are more prevalent in subtype-B than in non-B subtypes, whereas mutations such as L74I/M, T97A, L101I, E157Q, T214A, and V201I are more prevalent in non-B subtypes compared to HIV-1 subtype B.

Drug resistance emergence in macaques administered cabotegravir long-acting for pre-exposure prophylaxis during acute SHIV infection.

PMID: 31043606 2019 Nature communications

Table: E92E/Q

Table: E92Q

Discussion: Although the in vitro replication capacity mutants containing E92Q or G118R was markedly reduced, their transmission fitness is not known as it is also unknown if their transmission potential may be increased if viremias are high as it is the case of acute HIV infection.

Filtrator